Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients

被引：0
|
作者：
Zhang, H. [1 ]
Cun, F. S. [1 ]
机构：
[1] Nanjing Chest Hosp, Resp Med, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S1586 / S1587
页数：2
相关论文
共 50 条
  • [21] Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
    Zhou, J.
    Zhou, J.
    Zheng, J.
    Wang, K.
    Tang, K.
    Lu, D.
    Cui, J.
    Zhu, D.
    Wang, Y.
    Zhao, Y.
    Xing, L.
    Ding, L.
    Shi, X.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
  • [22] First-line treatment outcomes of CML patients in a real-world data setting in Lebanon.
    Nasr, Fadi
    Yehia, Intissar
    El Khoury, Reem
    Diab, Saada
    Ghoche, Ahmad
    Nasr, Lewis
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm
    Nieva, J.
    Chapaneri, J.
    Lau, Y. K.
    Cooper, M.
    Karia, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S191
  • [24] Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment
    Wu, Q.
    Li, W.
    Wang, J. T.
    Pu, D.
    Li, Y.
    Xu, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S664 - S664
  • [25] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Jorge Nieva
    Karen L. Reckamp
    Danielle Potter
    Aliki Taylor
    Ping Sun
    Drugs - Real World Outcomes, 2022, 9 : 333 - 345
  • [26] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Nieva, Jorge
    Reckamp, Karen L.
    Potter, Danielle
    Taylor, Aliki
    Sun, Ping
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 333 - 345
  • [27] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
    Huang, M. J.
    Yu, M.
    Gong, Y. L.
    Li, Y. Y.
    Liu, Y. M.
    Peng, F.
    Yu, Y.
    Xiu, W. G.
    Wang, Y. S.
    Zou, B. W.
    Fan, H.
    Zhong, L. Q.
    Liu, T. Q.
    Wang, X. F.
    Xu, Y.
    Zhou, L.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S146
  • [28] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
    Halmos, Balazs
    Tan, Eng-Huat
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian J.
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward S.
    Melosky, Barbara L.
    Maerten, Angela
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
    Nieva, J.
    Reckamp, K.
    Taylor, A.
    Thakrar, B.
    Wong, J.
    Potter, D.
    Bakker, N.
    Rubinstein, W.
    Sun, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S399
  • [30] Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
    Shin, Ji Eun
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Shim, Byoung Yong
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345